VistaGen Therapeutics (VTGN) Projected to Post Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) will likely be announcing its Q3 2026 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $0.14 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.16 million. On average, analysts expect VistaGen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Performance

NASDAQ VTGN opened at $0.56 on Wednesday. VistaGen Therapeutics has a one year low of $0.50 and a one year high of $5.14. The company has a market capitalization of $22.30 million, a price-to-earnings ratio of -0.30 and a beta of 0.32. The company’s 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $2.86.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VTGN shares. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research note on Wednesday, December 17th. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new stake in shares of VistaGen Therapeutics during the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of VistaGen Therapeutics in the 3rd quarter valued at approximately $39,000. Millennium Management LLC acquired a new stake in VistaGen Therapeutics in the 3rd quarter worth approximately $73,000. Bank of America Corp DE grew its position in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in VistaGen Therapeutics during the 2nd quarter worth approximately $69,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.